Cwm LLC Buys 2,007 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CWM LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 96.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,081 shares of the biopharmaceutical company's stock after buying an additional 2,007 shares during the period. CWM LLC's holdings in Regeneron Pharmaceuticals were worth $2,588,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after buying an additional 686 shares during the last quarter. Proficio Capital Partners LLC increased its stake in Regeneron Pharmaceuticals by 30.5% during the fourth quarter. Proficio Capital Partners LLC now owns 308 shares of the biopharmaceutical company's stock valued at $219,000 after purchasing an additional 72 shares during the last quarter. American Assets Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $427,000. Madison Investment Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $4,591,000. Finally, Envestnet Portfolio Solutions Inc. increased its stake in Regeneron Pharmaceuticals by 36.2% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,684 shares of the biopharmaceutical company's stock valued at $1,912,000 after purchasing an additional 713 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. UBS Group boosted their target price on shares of Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the company a "neutral" rating in a research note on Friday, July 11th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $700.00 to $580.00 in a research report on Friday, May 30th. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $823.54.

Regeneron Pharmaceuticals Stock Down 1.4%

Shares of REGN traded down $7.48 during trading hours on Friday, reaching $542.52. The company's stock had a trading volume of 1,307,803 shares, compared to its average volume of 929,805. The firm has a market cap of $58.57 billion, a price-to-earnings ratio of 13.81, a P/E/G ratio of 2.01 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $544.44 and a two-hundred day moving average of $614.99.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $9.55 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.